TABLE 6.
Comparison with previous studies on platinum‐combination chemotherapy for patients with postoperative recurrent non‐small cell lung cancer previously treated with adjuvant platinum‐doublet chemotherapy.
| Author, Reference no. | n | Regimen | DCR (%) | ORR (%) | Median PFS (months) | Median OS (months) |
|---|---|---|---|---|---|---|
| Imai et al. 18 | 16 | Platinum/pemetrexed/±bevacizumab (n = 11) | 81.2 | 31.2 | 6.5 | 28.0 |
| Platinum/taxane/±bevacizumab (n = 3) | ||||||
| Other (n = 2) | ||||||
| Valdes et al. 19 | 25 | Platinum/taxane a | 66.7 | 29.2 | Not shown | 18.4 |
| Other | ||||||
| Present study | 30 | Platinum/pemetrexed/±bevacizumab (n = 15) | 80.0 | 46.7 | 10.2 | 37.5 |
| Platinum/taxane/±bevacizumab (n = 6) | ||||||
| Platinum/other (n = 2) | ||||||
| Platinum‐combination with ICI (n = 7) |
Abbreviations: DCR, disease control rate; ICI, immune‐checkpoint inhibitor; ORR, objective response rate; OS, overall survival; PFS, progression‐free survival.
a
The number of patients was not described.